| Name | Title | Contact Details |
|---|---|---|
Samuel Maeder |
Information Security Director | Profile |
MedCases Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avicenna Laser Technology is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Watercrest Senior Living Group specializes in the development and operations of assisted living and memory care communities, market repositioning and advisory services. The principals have an impressive track record of leading the turnaround of underperforming assets and the stabilization of newly built communities. Partnering with a wide variety of stakeholders such as land owners, real estate developers, investors, financial institutions, and REITs, Watercrest Senior Living Group focuses on its core strengths, operations management of assisted living and memory care communities and the development of servant leaders. With state of the art information systems and key vendor partnerships, we are well positioned to efficiently assimilate both existing assisted living and memory care communities and the next generation of senior living product.
The Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services, is one of the largest purchasers of health care in the world. Medicare, Medicaid, and the Childrens Health Insurance Program (CHIP) provide health care for one in four Americans.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.